新华制药 (000756)
SHANDONG XINHUA PHARMACEUTICAL COMPANY LIMITED
K-Line Chart
No K-line data available
Company NameShandong Xinhua Pharmaceutical Co., Ltd.
Listing Date1997-08-06
Issue Price3.45RMB
Registered Capital68977.653510k RMB
Legal RepresentativeHe Tongqing
Registered AddressChemical Industry Zone, High-tech Industrial Development Zone, Zibo City, Shandong Province
IndustryChemical Pharmaceuticals
Main BusinessDevelopment, manufacturing, and sales of chemical APIs (Active Pharmaceutical Ingredients), pharmaceutical preparations, chemical products, and other related products.
Company ProfileShandong Xinhua Pharmaceutical Co., Ltd. is currently a National High-Tech Enterprise, a Key High-Tech Enterprise under the National Torch Program, and a backbone enterprise in the National Torch Program's Biomedicine Industry Base. The company has established six major technology platforms, including a novel drug delivery system technology platform, within its corporate postdoctoral workstation. It has also set up seven research centers covering areas such as medicinal chemistry and quality research. The company has formed strategic collaborations with Shandong University, Chinese Academy of Medical Sciences, Tsinghua University, Shenyang Pharmaceutical University, Qingdao University of Science and Technology, etc. Its R&D talent team consists of 2 academicians, 3 Taishan Industry Leading Talents, 1 provincial-level expert with outstanding contributions, over 10 PhDs, more than 200 master's degree holders, and over 1,000 bachelor's degree holders, providing valuable intellectual and technical support for the company's innovation and development. Currently, the company holds 102 national new drug production approvals, including 7 Class I new drug approvals and 18 Class II new drug approvals. The company focuses on eight major therapeutic areas, including pain control, cardiovascular and cerebrovascular diseases, diabetes, and digestive system disorders, with over 100 new products under research and development.
Stock Details
1. Key Indicators
- Total Shares(W): 68977.65
- Circulating A-Shares(W): 49262.39
- Earnings Per Share(RMB): 0.3700
- Net Assets Per Share(RMB): 7.4648
- Operating Revenue(W RMB): 676262.09
- Total Profit(W RMB): 30599.66
- Net Profit Attributable to Parent(W RMB): 25622.07
- Net Profit Growth Rate(%): -25.53
- Weighted Return on Equity(%): 5.0100
- Operating Cash Flow Per Share(RMB): 0.4670
- Undistributed Profit Per Share(RMB): 3.8189
- Capital Reserve Per Share(RMB): 1.7481
2. Main Business
The main business covers:
- Development, manufacturing and sales of chemical APIs
- Development, manufacturing and sales of pharmaceutical preparations
- Development, manufacturing and sales of pharmaceutical intermediates
- Development, manufacturing and sales of other products
3. Company Basic Information
- Company Name: Shandong Xinhua Pharmaceutical Company Limited
- Listing Date: 1997-08-06
- Industry: Pharmaceutical Manufacturing
- Address: No.1 Lutai Avenue, High-tech Zone, Zibo City, Shandong Province
- Website: www.xhzy.com
- Company Profile：The company's predecessor was the original Shandong Xinhua Pharmaceutical Factory, founded in 1943, initially producing sanitary materials. From the 1950s to the late 1960s, Xinhua Pharmaceutical Factory participated in the construction and management of many domestic pharmaceutical factories due to its accumulated rich experience in pharmaceutical production. In 1993, the original Shandong Xinhua Pharmaceutical Factory exclusively initiated the establishment of the company through a directed placement. In 1996, the company issued 150 million H-shares.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Hualu Holding Group Co., Ltd. | General Legal Person | 20486.41 | 41.59 |
| 2 | Hualu Investment Development Co., Ltd. | General Legal Person | 3709.20 | 7.53 |
| 3 | Hong Kong Securities Clearing Company Ltd. | Northbound Capital | 313.37 | 0.64 |
| 4 | China Southern CSI 1000 ETF | Fund | 271.79 | 0.55 |
| 5 | ChinaAMC CSI 1000 ETF | Fund | 161.33 | 0.33 |
| 6 | GF CSI 1000 ETF | Fund | 124.70 | 0.25 |
| 7 | <值> | <值> | <值> | <值> |
| 8 | <值> | <值> | <值> | <值> |
| 9 | <值> | <值> | <值> | <值> |
| 10 | <值> | <值> | <值> | <值> |
5. Concept Sectors
- H-Share
- New Retail
- Alibaba Concept
- Vitamins
- Medical Aesthetics Concept
- Helicobacter Pylori
- Assisted Reproduction
- Hepatitis Concept
- Innovative Drugs
- Synthetic Biology
- Pet Economy
- Margin Trading & Securities Lending
Remarks
- Data update date: 2026-01-01
- Data source: Public Market Information